Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

Purpose To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens. Methods ER analyses were conducted using pooled NS...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology Jg. 84; H. 6; S. 1257 - 1267
Hauptverfasser:	Morrissey, Kari M., Marchand, Mathilde, Patel, Hina, Zhang, Rong, Wu, Benjamin, Phyllis Chan, H., Mecke, Almut, Girish, Sandhya, Jin, Jin Y., Winter, Helen R., Bruno, René
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2019 Springer Nature B.V
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacokinetics Bladder cancer Body weight Cancer Research carcinoma Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - mortality Clinical Trials, Phase I as Topic Clinical Trials, Phase III as Topic Computer Simulation Datasets as Topic Dosage Dose-Response Relationship, Drug Drug Administration Schedule Drug development Female Humans Immunotherapy Infusions, Intravenous lung neoplasms Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Medicine Medicine & Public Health Models, Biological Monoclonal antibodies Monte Carlo Method Non-small cell lung carcinoma Oncology Original Original Article pharmacokinetics Pharmacology/Toxicology Randomized Controlled Trials as Topic Safety Survival Analysis Targeted cancer therapy Treatment Outcome Urologic Neoplasms - drug therapy Urologic Neoplasms - mortality Urothelial cancer Urothelial carcinoma PD-L1 Population pharmacokinetics Exposure–response Atezolizumab
ISSN:	0344-5704, 1432-0843, 1432-0843
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!